June 30, 2017 / 1:34 PM / in 5 months

BRIEF-Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults

June 30 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults

* Aeterna Zentaris - “Believe FDA review period of NDA will be up to 6 months, setting stage for potential approval of product late in 2017, early in 2018”

* Aeterna Zentaris Inc - Focus is to be prepared to launch Macrilen in Q1 of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below